US2011033929A1PendingUtilityA1
Uses of antibodies to mammalian dc langerhans cell antigen
Est. expirySep 25, 2018(expired)· nominal 20-yr term from priority
Inventors:Valerie Duvert-FrancesJean-Jacques PinJenny ValladeauValerie ClairSem SaelandSerge Lebecque
C07K 16/2851C07K 14/705
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to purified mammalian DC cell surface protein, designated Langerin, nucleic acids encoding Langerin, and antibodies which specifically bind Langerin.
Claims
exact text as granted — not AI-modified1 - 15 . (canceled)
16 . An antibody conjugate comprising: an antibody or antigen binding fragment thereof which specifically binds to a polypeptide comprising the amino acid of SEQ ID NO: 2 conjugated to an antigen.
17 . The antibody conjugate of claim 16 , wherein said antibody or antigen binding fragment thereof is a monoclonal antibody or an antigen binding fragment thereof.
18 . The antibody conjugate of claim 17 , wherein said monoclonal antibody or antigen binding fragment thereof is the monoclonal antibody having ATCC Accession No. HB-12576 or an antigen binding fragment thereof.
19 . A method of targeting antigen to dendritic cells comprising the use of an antibody conjugate, said antibody conjugate comprising an antibody or antigen binding fragment thereof which specifically binds to a polypeptide comprising the amino acid of SEQ ID NO: 2 conjugated to an antigen.
20 . The method of claim 19 , wherein said antibody or antigen binding fragment thereof is a monoclonal antibody or an antigen binding fragment thereof.
21 . The method of claim 20 , wherein said monoclonal antibody or antigen binding fragment thereof is the monoclonal antibody having ATCC Accession No. HB-12576 or an antigen binding fragment thereof.Join the waitlist — get patent alerts
Track US2011033929A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.